Key result
FOLFIRI3-bevacizumab as first-line therapy for metastatic colorectal cancer achieved an objective response rate of 66.7%, though high baseline angiopoietin-2 levels correlated with poorer survival outcomes.
Why the study?
Does FOLFIRI3-bevacizumab improve response rates in patients with non-previously treated metastatic colorectal cancer?
Does FOLFIRI3-bevacizumab improve response rates in patients with non-previously treated metastatic colorectal cancer?
FOLFIRI3-bevacizumab as front-line therapy for mCRC shows promising response rates, with high baseline angiopoietin-2 levels predicting unfavorable clinical outcomes.
Answers are grounded in this paper and cite their sources.
FOLFIRI3-bevacizumab shows activity in first-line mCRC; leaves open comparative efficacy versus standard regimens in randomized trials.
BACKGROUND: Optimization of chemotherapy effectiveness in metastatic colorectal cancers (mCRC) is a major endpoint to enhance the possibility of curative intent surgery. FOLFIRI3 has shown promising results as second-line chemotherapy for mCRC patients previously exposed to oxaliplatin. The clinical efficacy of FOLFIRI3 was never determined in association with bevacizumab in non-previously treated mCRC patients. METHODS: We conducted a phase II clinical trial to characterize the response rate and toxicity profile of FOLFIRI3-bevacizumab as initial treatment for mCRC. Sixty-one patients enrolled in 3 investigation centers were treated with FOLFIRI3-bevacizumab (median of 10 cycles) followed by a maintenance therapy combining bevacizumab and capecitabine. Levels of plasma angiopoietin-2 (Ang-2) were measured by enzyme-linked immunosorbent assay at baseline. RESULTS: Overall response rate (ORR) was 66.7% (8% of complete and 58% of partial responses). The disease control rate was 91.7%. After a median time of follow-up of 46.7 months, 56 patients (92%) had progressed or died. The median progression free survival (PFS) was 12.7 months (95% confidence interval (CI) 9.7-15.8 months). The median overall survival (OS) was 24.5 months (95% CI: 10.6-38.3 months). Twenty-one patients underwent curative intent-surgery including 4 patients with disease initially classified as unresectable. Most common grade III-IV toxicities were diarrhea (15%), neutropenia (13%), asthenia (10%), and infections (4%). Hypertension-related medications needed to be increased in 3 patients. In multivariate analysis, surgery of metastases and Ang-2 levels were the only independent prognostic factors for PFS and OS. Indeed, baseline level of Ang-2 above 5 ng/mL was confirmed as an independent prognostic factor for progression free survival (HR = 0.357; 95% CI: 0.168-0.76, p = 0.005) and overall survival (HR = 0.226; 95% CI: 0.098-0.53, p = 0.0002). CONCLUSIONS: As front-line therapy, FOLFIRI-3-bevacizumab is associated with an acceptable toxicity and induced promising objective response rates. However, unfavorable clinical outcomes were observed in patients with high levels of angiopoietin-2.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2013) studied First-line metastatic colorectal cancer (n=61). FOLFIRI3-bevacizumab was evaluated on Objective response rate (ORR) (95% CI 55-79). FOLFIRI3-bevacizumab as first-line therapy for metastatic colorectal cancer achieved an objective response rate of 66.7%, though high baseline angiopoietin-2 levels correlated with poorer survival outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: